What is the initial dose of intravenous (IV) epinephrine for a patient with severe asthma and life-threatening respiratory distress, hypoxia, or hypercapnia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IV Epinephrine Dosing for Life-Threatening Asthma

For life-threatening asthma with severe respiratory distress, hypoxia, or hypercapnia, administer IV epinephrine as a bolus of 20-200 mcg (0.02-0.2 mg) followed by continuous infusion at 1-10 mcg/min, titrated to clinical response. 1

Initial Bolus Dosing

  • Start with 20 mcg IV bolus for patients with life-threatening features who have not responded to nebulized beta-agonists and IV corticosteroids 1
  • Escalate to 50-200 mcg bolus if inadequate response after 2 minutes 1, 2
  • Prepare by diluting 1 mg (1 mL) of 1:1000 epinephrine in 10 mL normal saline, then administer 0.2-2 mL (20-200 mcg) over several minutes 3

Continuous Infusion Protocol

Standard preparation method: Add 1 mg (1 mL) of 1:1000 epinephrine to 250 mL D5W to yield 4 mcg/mL concentration 3

  • Initial infusion rate: 1-4 mcg/min (15-60 drops/min with microdrop apparatus) 3
  • Titrate upward to maximum 10 mcg/min based on clinical response and side effects 3
  • Alternative concentration: 1 mg in 100 mL saline (1:100,000 solution) infused at 30-100 mL/h (5-15 mcg/min) if infusion pump available 3

Clinical Context for IV Epinephrine Use

Reserve IV epinephrine for patients who:

  • Have failed multiple doses of nebulized beta-agonists (salbutamol 5 mg continuously) 3
  • Have received IV hydrocortisone 200 mg and show no improvement 3
  • Demonstrate life-threatening features: PaCO2 >45 mmHg, severe hypoxia (PaO2 <60 mmHg), silent chest, or altered mental status 3

Critical Safety Considerations

Continuous monitoring is mandatory when administering IV epinephrine 3, 2:

  • Every-minute blood pressure and pulse measurements 3
  • Continuous ECG monitoring if available 3
  • Pulse oximetry and arterial blood gases 3

Adverse events occur in approximately 30% of cases but are mostly minor (tachycardia, tremor); major adverse events (arrhythmias, chest pain, hypotension) occur in only 3.6% 4. In younger adults with life-threatening asthma, IV epinephrine has been shown to be safe with no deaths, cardiac ischemia, or significant arrhythmias in case series 2.

Pediatric Dosing

  • Bolus dose: 0.01 mg/kg (0.1 mL/kg of 1:10,000 solution; maximum 0.3 mg) 3
  • Infusion by "rule of 6": 0.6 × body weight (kg) = mg diluted to 100 mL saline; then 1 mL/h delivers 0.1 mcg/kg/min 3

When NOT to Use IV Epinephrine

Do NOT give bolus IV epinephrine to patients already taking oral theophyllines without first checking levels, as this increases risk of toxicity 3. Instead, use IV aminophylline 250 mg over 20 minutes OR IV salbutamol/terbutaline 250 mcg over 10 minutes as alternatives 3.

Concurrent Essential Therapies

While preparing epinephrine infusion, ensure:

  • High-flow oxygen to maintain SpO2 >92% 3
  • IV hydrocortisone 200 mg every 6 hours (or prednisolone 30-60 mg PO if able to swallow) 3
  • Nebulized ipratropium 0.5 mg added to beta-agonists 3
  • IV fluid resuscitation as needed for hypotension 3

References

Research

Acute asthma and the life threatening episode.

Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 1999

Research

Intravenous epinephrine in life-threatening asthma.

Annals of emergency medicine, 2003

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.